Fixed-Dose Antihypertensive Composition for Better Treatment Adherence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for arterial hypertension, particularly in patients with chronic ischemic heart disease and heart failure, suffer from poor patient adherence due to complex drug regimens, adverse effects, and inadequate blood pressure control, despite the availability of multiple pharmacological classes.
Innovation Solution
A pharmaceutical composition combining β-blockers (bisoprolol and nebivolol), angiotensin II receptor inhibitors (candesartan), and diuretics (indapamide) in a single formulation, allowing for modular and tolerable dosages to interact with multiple pathogenic mechanisms, reducing side effects and improving adherence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple drugs are prescribed to manage hypertensive disease through different etiopathogenetic mechanisms, then blood pressure control effectiveness is improved, but treatment complexity and patient adherence deteriorate
Solution Approach 1:
The patent combines multiple active ingredients from different pharmacological classes (β-blockers, ACE inhibitors, sartans, α-lytics, diuretics) into a single fixed-dose combination tablet. This merging approach maintains the therapeutic benefits of multi-mechanism action while simplifying the treatment regimen to one daily pill, directly resolving the contradiction between effectiveness and complexity
Solution Approach 2:
The single tablet formulation serves multiple functions simultaneously by incorporating drugs that target different etiopathogenetic mechanisms of hypertension. This multi-functional design allows one medication to address multiple pathophysiological pathways, eliminating the need for multiple separate medications while maintaining comprehensive blood pressure control
2Reliability
If multiple drugs are prescribed at high dosages to achieve therapeutic objectives, then blood pressure reduction effectiveness is improved, but side effects and tolerability worsen
Solution Approach 1:
The fixed-dose combination tablet optimizes the dosage parameters of each active ingredient to achieve synergistic effects at lower individual doses. By carefully selecting specific dosages of each component drug, the formulation maintains effective blood pressure reduction while minimizing the side effects associated with high dosages of individual medications
3Reliability
If complex treatment plans are prescribed, then comprehensive disease management is improved, but patient adherence and communication deteriorate
Solution Approach 1:
The patent merges multiple treatment components into a single fixed-dose combination tablet, transforming a complex multi-drug regimen into one simple daily medication. This consolidation maintains comprehensive disease management while dramatically improving ease of operation and patient adherence by eliminating the need to take multiple separate pills
Data Source
AI summary
The present invention concerns a composition for the treatment of hypertensive patients, with chronic ischemic heart disease and heart failure. The invention provides a pharmaceutical composition comprising or consisting of an aliquot of: (a) at least one compound of the pharmacological class of β-blockers, such as bisoprolol and/or nebivolol; (b) a selective angiotensin II receptor (AT1) inhibitor belonging to the pharmacological class of sartans, such as candesartan. Components (a) and (b) can be associated with a third component (c) belonging to the pharmacological class of diuretics, such as indapamide. Components (a), (b) and optionally (c) are supplied in a single formulation.